Agilent Announces the NovoCyte Opteon, a Cutting-Edge Spectral Flow Cytometry Solution

Rhea-AI Summary

• English
• French
• German
• Italian
• Korean
• Spanish

Agilent Technologies Inc. (NYSE: A) has introduced the NovoCyte Opteon Spectral Flow Cytometer, a cutting-edge system that revolutionizes flow cytometry by offering advanced spectral capabilities and user-friendly design. This new addition to the NovoCyte family features three to five lasers, up to 73 detectors, and the ability to analyze over 40 markers simultaneously, providing researchers with unprecedented precision and flexibility in flow cytometry assays. The NovoCyte Opteon will be officially unveiled at the CYTO 2024 Conference in May 2024, marking a decade of innovation in the NovoCyte platform.

Positive

• The NovoCyte Opteon introduces advanced spectral capabilities and user-friendly features, setting a new standard in flow cytometry technology.

• The system allows for simultaneous analysis of over 40 markers, offering researchers unparalleled precision and flexibility in flow panel design.

• The NovoCyte Opteon represents a significant leap forward in flow cytometry technology, with configurations supporting up to 73 high-quality detectors and three to five lasers.

• Agilent's NovoCyte portfolio celebrates a decade of innovation, with the introduction of the NovoCyte Opteon marking a milestone in cell analysis research.

Negative

• None.

Latest addition to the NovoCyte family celebrates a decade of flow cytometry excellence

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) has announced the NovoCyte Opteon Spectral Flow Cytometer, propelling flow cytometry into a new era of and accessibility. This cutting-edge system sets a gold standard for acquiring, analyzing, and reporting flow data across diverse domains—from basic research to drug discovery and therapy development.

The NovoCyte Opteon represents a significant leap forward in flow cytometry technology, with configurations ranging from three to five lasers and support for up to 73 high-quality detectors. It meets researchers’ needs for sophisticated, large-panel flow cytometry assays while maintaining the easy-to-use features of the NovoCyte portfolio.

Researchers can now explore cellular mysteries with unparalleled precision, simultaneously analyzing over 40 markers, providing great flexibility in flow panel design.

“2024 marks the 10^th anniversary of the introduction of NovoCyte flow cytometry platform. Over the years, the technology-advancing and capability-enhancing NovoCyte Quanteon, Advanteon, and Penteon were added into NovoCyte portfolio, helping scientists to advance their cell analysis research,” stated Xiaobo Wang, vice president and general manager of Agilent’s Cell Function and Phenotyping Business.

“The addition of the new NovoCyte Opteon couples the inherent power of spectral flow cytometry with a highly intuitive analytical software package which streamlines workflow for high-dimensional, multi-parametric flow cytometry assays while being exceptionally easy to use, maintain and automate,” Wang added.

Flow cytometry is a crucial technology employed globally, spanning academic centers, biotech firms, and pharmaceutical companies. The NovoCyte Opteon assumes a pivotal role, empowering researchers with advanced spectral capabilities, user-friendly design, and customizable features to align with specific research requirements. Advanced engineering with proprietary technology ensures optimized light collection and electronic signal collection, real-time monitoring, and consistent, reliable data acquisition.

Agilent will officially unveil the NovoCyte Opteon at the CYTO 2024 Conference in Edinburgh, Scotland, happening May 4 – 8, 2024.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240501954210/en/

Catherine Kaye

Agilent Technologies

+447775410632

catherine.kaye@agilent.com

Source: Agilent Technologies Inc.

FAQ

<p>What is the name of the new spectral flow cytometer introduced by Agilent Technologies?</p>

The new spectral flow cytometer introduced by Agilent Technologies is called the NovoCyte Opteon.

<p>How many lasers are supported by the NovoCyte Opteon system?</p>

The NovoCyte Opteon system supports configurations ranging from three to five lasers.

<p>How many detectors can the NovoCyte Opteon system support?</p>

The NovoCyte Opteon system can support up to 73 high-quality detectors.

<p>When will Agilent officially unveil the NovoCyte Opteon?</p>

Agilent will officially unveil the NovoCyte Opteon at the CYTO 2024 Conference in Edinburgh, Scotland, happening May 4 – 8, 2024.

<p>Who is the vice president and general manager of Agilent’s Cell Function and Phenotyping Business?</p>

Xiaobo Wang is the vice president and general manager of Agilent’s Cell Function and Phenotyping Business.